Extended Data Fig. 2: Gene marking level. | Nature Medicine

Extended Data Fig. 2: Gene marking level.

From: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome

Extended Data Fig. 2: Gene marking level.The alternative text for this image may have been generated using AI.

Panel A, the VCN in the bone marrow (BM, white) subpopulations versus the peripheral blood (black) subpopulations in patients P2, P4 and P5; Panel B, VCN levels in the initial CD34 + drug product versus myeloid CD15 + cells 48 months after GT. Panel C, The Spearman correlation between the level of gene marking in CD15 + 48 months after GT and the number of corrected CD34 + cells infused per kilogram, for each patient. The pvalue (p) was calculated by using two-sided Spearman’s rank correlation test, r is Spearman’s rank correlation coefficient. A regression line is represented in black, the confidence interval in grey.

Back to article page